Department of Surgery, Tianjin Medical University, Tianjin, 300070, China.
Department of Surgery, Tianjin Nankai Hospital, Nankai Clinical School of Medicine, 122 Sanwei Road, Nankai District, Tianjin, 300110, China.
World J Emerg Surg. 2023 Jan 27;18(1):9. doi: 10.1186/s13017-023-00479-7.
A series of randomized controlled trials have investigated the efficacy and safety of different timings of interventions and methods of intervention. However, the optimal treatment strategy is not yet clear.
We searched PubMed, EMBASE, ClinicalTrials.gov and the Cochrane Library until November 30, 2022. A systematic review and Bayesian network meta-analysis were performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Trials comparing different treatment strategies for necrotizing pancreatitis were included. This study was registered in the Prospective Register of Systematic Reviews (CRD42022364409) to ensure transparency.
We analyzed a total of 10 studies involving 570 patients and 8 treatment strategies. Although no statistically significant differences were identified comparing odds ratios, trends were confirmed by the surface under the cumulative ranking (SUCRA) scores. The interventions with a low rate of mortality were delayed surgery (DS), delayed surgical step-up approach (DSU) and delayed endoscopic step-up approach (DEU), while the interventions with a low rate of major complications were DSU, DEU and DS. According to the clustered ranking plot, DSU performed the best overall in reducing mortality and major complications, while DD performed the worst. Analysis of the secondary endpoints confirmed the superiority of DEU and DSU in terms of individual components of major complications (organ failure, pancreatic fistula, bleeding, and visceral organ or enterocutaneous fistula), exocrine insufficiency, endocrine insufficiency and length of stay. Overall, DSU was superior to other interventions.
DSU was the optimal treatment strategy for necrotizing pancreatitis. Drainage alone should be avoided in clinical practice. Any interventions should be postponed for at least 4 weeks if possible. The step-up approach was preferred.
一系列随机对照试验已经研究了不同干预时机和干预方法的疗效和安全性。然而,最佳治疗策略尚不清楚。
我们检索了 PubMed、EMBASE、ClinicalTrials.gov 和 Cochrane 图书馆,截至 2022 年 11 月 30 日。按照系统评价和荟萃分析的 Preferred Reporting Items(PRISMA)指南进行系统评价和贝叶斯网络荟萃分析。纳入比较坏死性胰腺炎不同治疗策略的试验。本研究在系统评价注册中心(CRD42022364409)注册,以确保透明度。
我们分析了共 10 项研究,涉及 570 例患者和 8 种治疗策略。尽管比较优势比没有统计学意义,但表面累积排序曲线下面积(SUCRA)评分证实了趋势。死亡率较低的干预措施是延迟手术(DS)、延迟手术升级方法(DSU)和延迟内镜升级方法(DEU),而主要并发症发生率较低的干预措施是 DSU、DEU 和 DS。根据聚类排序图,DSU 在降低死亡率和主要并发症方面总体表现最佳,而 DD 表现最差。对次要终点的分析证实,DEU 和 DSU 在主要并发症(器官衰竭、胰瘘、出血、内脏器官或肠皮肤瘘)、外分泌功能不全、内分泌功能不全和住院时间等方面具有优越性。总体而言,DSU 优于其他干预措施。
DSU 是治疗坏死性胰腺炎的最佳策略。在临床实践中应避免单独引流。如果可能,任何干预措施都应至少推迟 4 周。应优先采用升级方法。